Dogwood Therapeutics (DWTX) Price & Analysis

Compare

249 Followers

DWTX Stock Chart & Stats

$5.76

-$0.11(-4.15%)

At close: Jan 08 4:00 PM EST

$5.76

-$0.11(-4.15%)

Day’s Range― - ―

52-Week Range$1.62 - $29.28

Previous CloseN/A

Volume14.38K

Average Volume (3M)1.54M

Market Cap

$13.21M

Enterprise Value$96.56M

Total Cash (Recent Filing)$13.40M

Total Debt (Recent Filing)$75.85M

Price to Earnings (P/E)―

Beta3.37

Next Earnings

Nov 06, 2025

EPS Estimate

-1.16

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.99

Shares Outstanding2,293,162

10 Day Avg. Volume77,367

30 Day Avg. Volume1,536,657

Financial Highlights & Ratios

PEG Ratio>-0.01

Price to Book (P/B)0.04

Price to Sales (P/S)0.00

P/FCF Ratio-0.29

Enterprise Value/Market Cap7.31

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-2.08K

Enterprise Value/Ebitda-3.98

Forecast

1Y Price Target

$21.00

Price Target Upside264.58% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

Bulls Say, Bears Say

Bulls Say

Financial PerformanceAnalyst's price target for Dogwood Therapeutics shares has been raised, reflecting increased confidence in the company's future financial performance due to the new asset.

Licensing AgreementDogwood Therapeutics has secured a global licensing agreement with Serpin Pharma for the rights to SP16 for cancer-related pain indications, which could enhance the company's product offerings.

Study FundingThe upcoming Phase 1b study for SP16 is fully funded through a grant, which reduces financial risk and burden on Dogwood Therapeutics.

Bears Say

Financial LossThe company reported no revenues in the quarter and a net loss of $1.99 per share, which was worse than the consensus estimated net loss of $0.79 per share.

Net Loss ImpactDogwood reported a net loss of $3.8M, which impacts its financial position.

Dogwood Therapeutics News

Dogwood to present on Halneuron pain research program

Dogwood (DWTX) Therapeutics announced that its Chief Medical Officer will present an overview of the Halneuron pain management...

13d ago

DWTX

Dogwood files to sell 28.04M shares of common stock for holders

16:15 EDT Dogwood (DWTX) files to sell 28.04M shares of common stock for holders Published first on TheFly...

19d ago

DWTX

Dogwood price target raised to $12 from $10 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Dogwood (DWTX) to $12 from $10 and keeps a Buy...

20d ago

DWTX

Dogwood secures royalty free license to develop, commercialize SP16

Dogwood (DWTX) Therapeutics announced that in an all-stock transaction, it has secured a royalty free, global license to...

21d ago

DWTX

Dogwood Therapeutics Announces Business Combination Plans

Dogwood Therapeutics ( ($DWTX) ) has provided an announcement. On October 9, 2025, Dogwood Therapeutics posted a presentation...

11d ago

DWTX

Strategic Advancements and Growth Potential: Dogwood Therapeutics’ Acquisition of SP16

Dogwood Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jason McCarthy from...

19d ago

DWTX

Dogwood Therapeutics Secures Licensing Deal with Serpin Pharma

Dogwood Therapeutics ( ($DWTX) ) has shared an announcement. On September 29, 2025, Dogwood Therapeutics entered into an...

21d ago

DWTX

Buy Rating for Dogwood Therapeutics: Promising Phase 2b Study Results and Strategic Financial Positioning

H.C. Wainwright analyst Sean Lee CFA has maintained their bullish stance on DWTX stock, giving a Buy rating...

2M ago

DWTX

Dogwood Therapeutics Reports Q2 2025 Financial Results

Virios Therapeutics, Inc. ( ($DWTX) ) has released its Q2 earnings. Here is a breakdown of the information...

2M ago

DWTX

Dogwood reports Q2 EPS ($1.99) vs ($1.15) last year

“With no FDA approved treatments to manage the neuropathic pain often resulting from chemotherapy treatment, we have the...

2M ago

DWTX

Dogwood Therapeutics Approves CFO Salary Increase

Dogwood Therapeutics ( ($DWTX) ) has provided an announcement. On June 27, 2025, Dogwood Therapeutics, Inc. announced that...

4M ago

DWTX

Dogwood Therapeutics Approves Equity Plan Amendment

Dogwood Therapeutics ( ($DWTX) ) just unveiled an announcement. On June 18, 2025, Dogwood Therapeutics, Inc. held its...

4M ago

DWTX

Dogwood files $150M mixed securities shelf

17:27 EDT Dogwood (DWTX) files $150M mixed securities shelf Published first on TheFly – the ultimate source for...

5M ago

DWTX

Promising Growth Potential for Dogwood Therapeutics with Halneuron’s Development and Strong Financial Position

In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Dogwood Therapeutics (DWTX...

5M ago

DWTX

DWTX FAQ

What was Dogwood Therapeutics’s price range in the past 12 months?

Dogwood Therapeutics lowest stock price was $1.62 and its highest was $29.28 in the past 12 months.

What is Dogwood Therapeutics’s market cap?

Dogwood Therapeutics’s market cap is $13.21M.

When is Dogwood Therapeutics’s upcoming earnings report date?

Dogwood Therapeutics’s upcoming earnings report date is Nov 06, 2025 which is in 17 days.

How were Dogwood Therapeutics’s earnings last quarter?

Dogwood Therapeutics released its earnings results on Aug 13, 2025. The company reported -$1.99 earnings per share for the quarter, missing the consensus estimate of -$0.79 by -$1.2.

Is Dogwood Therapeutics overvalued?

According to Wall Street analysts Dogwood Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Dogwood Therapeutics pay dividends?

Dogwood Therapeutics does not currently pay dividends.

What is Dogwood Therapeutics’s EPS estimate?

Dogwood Therapeutics’s EPS estimate is -1.16.

How many shares outstanding does Dogwood Therapeutics have?

Dogwood Therapeutics has 2,293,162 shares outstanding.

What happened to Dogwood Therapeutics’s price movement after its last earnings report?

Dogwood Therapeutics reported an EPS of -$1.99 in its last earnings report, missing expectations of -$0.79. Following the earnings report the stock price went down -1.031%.

Which hedge fund is a major shareholder of Dogwood Therapeutics?

Currently, no hedge funds are holding shares in DWTX

Company Description

Dogwood Therapeutics

Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It also develops IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Virios Therapeutics, Inc. and changed its name to Dogwood Therapeutics, Inc. in October 2024. The company was founded in 2012 and is headquartered in Alpharetta, Georgia.

Dogwood Therapeutics (DWTX) Earnings & Revenues

Historic Earnings Reports

DWTX Stock 12 Month Forecast

Average Price Target

$21.00

▲(264.58% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","31":"$31","9.25":"$9.25","16.5":"$16.5","23.75":"$23.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":30,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$30.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":21,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$21.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$12.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,9.25,16.5,23.75,31],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2024","6":"Oct<br/>2024","9":"Apr<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.81,6.747692307692308,8.685384615384615,10.623076923076923,12.560769230769232,14.498461538461537,16.436153846153847,18.373846153846156,20.31153846153846,22.24923076923077,24.186923076923076,26.124615384615385,28.062307692307694,{"y":30,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.81,6.055384615384615,7.30076923076923,8.546153846153846,9.791538461538462,11.036923076923078,12.282307692307693,13.527692307692309,14.773076923076925,16.01846153846154,17.263846153846156,18.509230769230772,19.754615384615384,{"y":21,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.81,5.363076923076923,5.916153846153846,6.469230769230769,7.022307692307692,7.575384615384616,8.128461538461538,8.681538461538462,9.234615384615385,9.787692307692307,10.340769230769231,10.893846153846155,11.446923076923078,{"y":12,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":12.88,"date":1698796800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":8.54,"date":1709251200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":11,"date":1714521600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":5.38,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.55,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.15,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.9,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.37,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.79,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.92,"date":1743465600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":5.36,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.85,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.81,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >